Memorial Sloan Kettering establishes MSKCC India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Memorial Sloan Kettering Cancer Center has established MSKCC India to provide cancer patients in India with access to the institution’s oncologists, research, clinical trials, and education. 

MSKCC India will provide remote opinions via video or written consultations. A Memorial Sloan Kettering Cancer Center oncologist who specializes in a patient’s form of cancer will review their medical records, test results, and other materials and provide a comprehensive written opinion, meet with the patient virtually using telemedicine technology, or speak with the patient’s local oncologist about their diagnosis and care plan. 

In some cases, they may recommend that the patient travel to receive care at Memorial Sloan Kettering Cancer Center in New York City. Specific services include:

  • Pathology diagnosis
  • Radiology scan reviews
  • Next-generation sequencing (MSK-IMPACTTM) of a patient’s tumor and treatment recommendations
  • Travel assistance to New York City

Memorial Sloan Kettering Cancer Center has partnered with iCliniq, a global telemedicine provider based in India. 

MSKCC India will open a physical location in Chennai, centrally located for patients and staff members. This location will serve as a hub for medical staff who will help patients coordinate written or virtual consultations, and they will be able to communicate in English, Hindi, Urdu, Tamil, Telugu and Kannada. 

If necessary, employees will be able to collect medical records from patients’ homes, making the process more convenient for those utilizing this service. Patients across India will be able to obtain a remote opinion from experts at Memorial Sloan Kettering Cancer Center in the comfort of their home or any internet-enabled location without traveling to MSKCC India in Chennai.

Patients in India now can visit in.mskcc.org/india to learn more about MSKCC India and how to schedule a consultation with a Memorial Sloan Kettering Cancer Center expert.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login